JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$268.48
+0.87%Nov 2, 2026, 01:33 UTC
Hong Kong’s JOHNSON & JOHNSON charged two then-senior executives of JOHNSON & JOHNSON with conspiring to accept more than HK$75 million in bribes from a supplier in return for preferential treatment in vehicle procurement and maintenance business.
Source:Nov 1, 2026, 13:00 UTC
JOHNSON & JOHNSON announced clinical analysis results reporting positive survival and patient outcomes among 1,379 high-risk percutaneous coronary intervention patients supported with Impella heart pumps.
Source:Oct 25, 2026, 14:24 UTC
JOHNSON & JOHNSON announced new Phase 1b/2 JOHNSON & JOHNSON Cohort 5 results for subcutaneous RYBREVANT plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in first-line treatment of certain advanced head and neck cancers.
Oct 24, 2026, 12:54 UTC
JOHNSON & JOHNSON announced new Phase 3 JOHNSON & JOHNSON substudy results comparing perioperative apalutamide plus androgen deprivation therapy with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer.
Source:Oct 23, 2026, 14:41 UTC
JOHNSON & JOHNSON shares reclaimed their 50-day simple moving average.
Source:Oct 23, 2026, 12:10 UTC
The UK approved JOHNSON & JOHNSON's oral psoriasis pill.
Source:Oct 23, 2026, 04:00 UTC
SMITH & NEPHEW PLC was in talks to combine with JOHNSON & JOHNSON’s orthopaedics unit, but the talks fell apart after SMITH & NEPHEW PLC refused to agree to the unit’s former CEO leading the combined business.
Oct 22, 2026, 11:45 UTC
JOHNSON & JOHNSON reported first real-world VARIPULSE Pro Platform data and 12-month OMNYPULSE Platform outcomes for atrial fibrillation treatment at JOHNSON & JOHNSON 2026.
Oct 22, 2026, 07:09 UTC
China's National Medical Products Administration approved JOHNSON & JOHNSON's Tecvayli (teclistamab) for an additional indication in adults with relapsed or refractory multiple myeloma after at least one prior line of therapy, including an anti-CD38 monoclonal antibody and lenalidomide.
Source:Oct 20, 2026, 11:45 UTC
JOHNSON & JOHNSON launched the Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter, which it says cuts IVL treatment time in half.
Oct 20, 2026, 06:00 UTC
JOHNSON & JOHNSON announced it will showcase its collaboration with the Department of Health – Abu Dhabi at the Future Health Summit 2026.
Source:Oct 19, 2026, 12:00 UTC
JOHNSON & JOHNSON announced Phase 3 FUZION study results showing TREMFYA maintained or improved fistula remission through Week 48 in adults with Crohn’s disease; remission in the 100 mg dose group increased from 28% at Week 24 to 35% at Week 48.
Source:Oct 14, 2026, 16:01 UTC
JOHNSON & JOHNSON shares fell 5.8% after its third-quarter earnings report.
Oct 14, 2026, 01:07 UTC
JOHNSON & JOHNSON shares fell more than 5% on Tuesday.
Source:Oct 13, 2026, 21:30 UTC
JOHNSON & JOHNSON raised its full-year forecast on October 13, 2026.
Source:Oct 13, 2026, 16:31 UTC
JOHNSON & JOHNSON weighed a possible orthopedics spinoff.
Source:Oct 13, 2026, 16:01 UTC
JOHNSON & JOHNSON reported third-quarter earnings above estimates but sales below expectations, with MedTech lagging.
Source:Oct 13, 2026, 15:07 UTC
JOHNSON & JOHNSON shares moved as the company reported earnings and raised its profit guidance.
Source:Oct 13, 2026, 12:47 UTC
JOHNSON & JOHNSON reported quarterly earnings of $2.59 per share, compared with $2.80 per share a year earlier.
Source:Oct 13, 2026, 10:37 UTC
JOHNSON & JOHNSON is reportedly inclined to spin off its hip and knee business.
Oct 13, 2026, 10:25 UTC
JOHNSON & JOHNSON set its quarterly dividend at $1.34 per share, unchanged from its previous regular cash dividend.
Oct 12, 2026, 20:05 UTC
JOHNSON & JOHNSON announced new Phase 3 JOHNSON & JOHNSON subgroup data showing consistent combined fistula remission outcomes with TREMFYA across clinically important subgroups of adults with Crohn’s disease and perianal fistula.
Source:Oct 12, 2026, 20:05 UTC
JOHNSON & JOHNSON announced three-year Phase 3 GALAXI 2 and 3 study data showing sustained clinical and endoscopic remission with TREMFYA in adults with moderately to severely active Crohn's disease, including clinical remission rates of up to 94%, endoscopic remission rates of up to 61%, and 90-day corticosteroid-free clinical remission in 88% of patients.
Source:Oct 9, 2026, 11:00 UTC
JOHNSON & JOHNSON announced new two-year Phase 3 JOHNSON & JOHNSON study results for ICOTYDE in adults and adolescents with plaque psoriasis, with nearly three-quarters achieving clear or almost clear skin and a continued favorable safety profile.
Source:Oct 9, 2026, 03:13 UTC
SanegeneBio and its wholly owned subsidiary SanegeneBio (Shanghai) signed a collaboration and license agreement with JOHNSON & JOHNSON to jointly develop novel oral medicines.
Source:Oct 4, 2026, 15:30 UTC
Oxford Science Enterprises appointed Dr Jeffrey Moore as senior partner and head of life sciences, succeeding Katya Smirnyagina, who will remain as an advisor.
Source:Oct 2, 2026, 10:00 UTC
Johnson & Johnson announced new two-year Phase 3 ICONIC-TOTALa data showing ICOTYDE (icotrokinra) achieved sustained skin clearance in patients with high-impact plaque psoriasis.
Source:Sep 29, 2026, 12:03 UTC
Johnson & Johnson announced new two-year findings on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis across 15 abstracts to be presented at the 2026 MGFA Scientific Session and AANEM Annual Meeting.
Source:Sep 27, 2026, 11:45 UTC
A UAE delegation led by Minister of Health and Prevention Ahmed bin Ali Al Sayegh visited healthcare and academic institutions in Boston and New York to explore strategic partnerships in genomic medicine, AI, digital health, rare diseases and specialised care.
Source:Sep 25, 2026, 15:03 UTC
Johnson & Johnson announced positive findings from clinical evaluations of its therapies Tremfya and Carvykti in psoriatic arthritis and multiple myeloma.
Source:
Page 1Next →